NAGE Q4 2019 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$393M

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M+44.4% YoY

Gross Profit

$7M57.0% margin

Operating Income

-$9M-67.7% margin

Net Income

-$9M-67.6% margin

EPS (Diluted)

$-0.15

QoQ Revenue Growth

+8.6%

Cash Flow

Operating Cash Flow

-$610,000

Free Cash Flow

-$890,000

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$40M

Total Liabilities

$20M

Stockholders' Equity

$20M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$9M	+44.4%
Gross Profit	$7M	$5M	+58.5%
Operating Income	-$9M	-$8M	-7.5%
Net Income	-$9M	-$8M	-7.7%